Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2523-8973
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19 ; volume:4 ; number:1 ; day:21 ; month:1 ; year:2022 ; pages:1-13 ; date:12.2022
SN comprehensive clinical medicine ; 4, Heft 1 (21.1.2022), 1-13, 12.2022
- Creator
-
Thoms, Brendan L.
Gosselin, Jeanne
Libman, Bonita
Littenberg, Benjamin
Budd, Ralph C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s42399-022-01121-4
- URN
-
urn:nbn:de:101:1-2022050219000610146477
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Thoms, Brendan L.
- Gosselin, Jeanne
- Libman, Bonita
- Littenberg, Benjamin
- Budd, Ralph C.
- SpringerLink (Online service)
Other Objects (12)
Baricitinib in der klinischen Routine - ein interdisziplinärer Erfahrungsaustausch : JAK-Inhibition bei atopischer Dermatitis
Ein Jahr Praxiserfahrung mit Baricitinib : der erste orale JAK-Inhibitor bei atopischer Dermatitits
Baricitinib reduces inflammation and improves cell homeostasis of HGPS fibroblasts by inhibiting JAK-STAT signaling
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Impact of JAK inhibitors tofacitinib and baricitinib on bone turnover during steady-state and pathological conditions
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Baricitinib in der klinischen Routine - ein interdisziplinärer Erfahrungsaustausch : JAK-Inhibition bei atopischer Dermatitis
Ein Jahr Praxiserfahrung mit Baricitinib : der erste orale JAK-Inhibitor bei atopischer Dermatitits
Baricitinib reduces inflammation and improves cell homeostasis of HGPS fibroblasts by inhibiting JAK-STAT signaling
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Impact of JAK inhibitors tofacitinib and baricitinib on bone turnover during steady-state and pathological conditions
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Baricitinib in der klinischen Routine - ein interdisziplinärer Erfahrungsaustausch : JAK-Inhibition bei atopischer Dermatitis
Ein Jahr Praxiserfahrung mit Baricitinib : der erste orale JAK-Inhibitor bei atopischer Dermatitits
Baricitinib reduces inflammation and improves cell homeostasis of HGPS fibroblasts by inhibiting JAK-STAT signaling
Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
Impact of JAK inhibitors tofacitinib and baricitinib on bone turnover during steady-state and pathological conditions
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
The effect of JAK inhibitors baricitinib and tofacitinib on Th17 cells, regulatory T cells and the Th17/Treg balance in patients with rheumatoid arthritis
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis